Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

MLA

Peter J. O’Dwyer, et al. Data from Open-Label, Phase I Study of Nivolumab Combined with Nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. Mar. 2023. EBSCOhost, https://doi.org/10.1158/1078-0432.c.6529076.v1.

APA

Peter J. O’Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, David J. Reiss, Thomas Lila, Hatem H. Soliman, Daniel Ricardo Carrizosa, Rishi Jain, Aparna Parikh, Martin Guiterrez, David M. Waterhouse, E. Gabriela Chiorean, Aparna Kaylan, Ben George, Edward J. Kim, … Zev A. Wainberg. (2023). Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer. https://doi.org/10.1158/1078-0432.c.6529076.v1

Chicago

Peter J. O’Dwyer, Teng Jin Ong, Chrystal U. Louis, Larry Lyons, Sibabrata Banerjee, Rafia Bhore, Daniel W. Pierce, et al. 2023. “Data from Open-Label, Phase I Study of Nivolumab Combined with Nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer,” March. doi:10.1158/1078-0432.c.6529076.v1.